| Symbol | CTMX |
|---|---|
| Name | CYTOMX THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 151 OYSTER POINT BLVD.,SUITE 400, SOUTH SAN FRANCISCO, California, 94080, United States |
| Telephone | +1 650 515-3185 |
| Fax | — |
| — | |
| Website | https://www.cytomx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001501989 |
| Description | CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. The company focuses on developing Probody therapeutics which addresses clinically-validated cancer targets in immuno-oncology that are difficult to drug and lead to concerns about damage to healthy tissues or toxicities. Additional info from NASDAQ: |
New Form SCHEDULE 13G - CytomX Therapeutics, Inc. <b>Filed:</b> 2026-08-03 <b>AccNo:</b> 0000070858-26-000395 <b>Size:</b> 171 KB
Read moreFuchs Charles S. 🟢 acquired 118.0K shares (1 derivative) of CytomX Therapeutics, Inc. (CTMX) at $3.24 Transaction Date: Jul 24, 2026 | Filing ID: 000345
Read moreNew Form 3 - CytomX Therapeutics, Inc. <b>Filed:</b> 2026-07-30 <b>AccNo:</b> 0001610717-26-000344 <b>Size:</b> 11 KB
Read moreCytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
Read more(99% Neutral) CYTOMX THERAPEUTICS, INC. (CTMX) Announces New Board Appointment
Read moreCytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors
Read moreSu Zhen 🟢 acquired 59.0K shares (1 derivative) of CytomX Therapeutics, Inc. (CTMX) at $2.96 Transaction Date: Jun 17, 2026 | Filing ID: 000280
Read more(99% Neutral) CYTOMX THERAPEUTICS, INC. (CTMX) Announces New Board Appointment
Read moreYoung Matthew P. 🟢 acquired 59.0K shares (1 derivative) of CytomX Therapeutics, Inc. (CTMX) at $2.96 Transaction Date: Jun 17, 2026 | Filing ID: 000279
Read moreMohindru Mani 🟢 acquired 59.0K shares (1 derivative) of CytomX Therapeutics, Inc. (CTMX) at $2.96 Transaction Date: Jun 17, 2026 | Filing ID: 000278
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06265688 | First In Human Study of CX-2051 in Advanced Solid Tumors | Phase1 | Solid Tumor, Adult | Recruiting | 2024-04-02 | 2029-03-31 | ClinicalTrials.gov |
| NCT05387265 | A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for … | Phase1 | Solid Tumors | Terminated | 2022-05-16 | 2025-06-04 | ClinicalTrials.gov |
| NCT04596150 | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and … | Phase2 | Neoplasms | Completed | 2020-12-29 | 2023-06-02 | ClinicalTrials.gov |
| NCT03706274 | PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Dr… | Phase1 | Solid Tumor, Adult | Withdrawn | 2020-01-01 | 2022-12-01 | ClinicalTrials.gov |
| NCT03993379 | PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination … | Phase2 | Solid Tumor | Terminated | 2019-11-20 | 2020-05-21 | ClinicalTrials.gov |
| NCT03543813 | PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational D… | Phase1 | Solid Tumor, Adult | Completed | 2018-06-15 | 2023-06-01 | ClinicalTrials.gov |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational D… | Phase1 | Solid Tumor, Adult | Terminated | 2017-06-01 | 2020-09-10 | ClinicalTrials.gov |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Dr… | Phase1 | Solid Tumor | Terminated | 2017-01-19 | 2020-10-27 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-188 | Other | Phase PHASE1 | Solid Tumor, Adult | WITHDRAWN | NCT03706274 |
| CX-2009 | Other | Phase PHASE1 | Solid Tumor, Adult | TERMINATED | NCT03149549 |
| CX-072 | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT04596150 |
| CX-2009 | Other | Phase PHASE2 | Neoplasms | COMPLETED | NCT04596150 |
| CX-2029 | Other | Phase PHASE1 | Solid Tumor, Adult | COMPLETED | NCT03543813 |
| vemurafenib | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT03013491 |
| ipilimumab | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT03013491 |
| CX-072 | Other | Phase PHASE1 | Solid Tumor | TERMINATED | NCT03013491 |
| CX-904 | Other | Phase PHASE1 | Solid Tumors | TERMINATED | NCT05387265 |
| Ipilimumab | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT03993379 |
| CX-072 | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT03993379 |
| pembrolizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06462794 |
| CX-801 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06462794 |
| Bevacizumab | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |
| CX-2051 | Other | Phase PHASE1 | Solid Tumor, Adult | RECRUITING | NCT06265688 |